Sweden
· Delayed Price · Currency is SEK Hansa Biopharma AB Statistics
Total Valuation
Hansa Biopharma AB has a market cap or net worth of SEK 2.08 billion. The enterprise value is 2.48 billion.
| Market Cap | 2.08B |
| Enterprise Value | 2.48B |
Important Dates
The last earnings date was Thursday, October 24, 2024.
| Earnings Date | Oct 24, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Hansa Biopharma AB has 67.81 million shares outstanding. The number of shares has increased by 15.98% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 67.81M |
| Shares Change (YoY) | +15.98% |
| Shares Change (QoQ) | +7.76% |
| Owned by Insiders (%) | 7.86% |
| Owned by Institutions (%) | 17.29% |
| Float | 38.23M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 9.54 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -3.79 |
| EV / Sales | 13.10 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -3.55 |
Financial Position
The company has a current ratio of 2.45
| Current Ratio | 2.45 |
| Quick Ratio | 2.44 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.37 |
| Interest Coverage | -6.57 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -37.08% |
| Return on Capital (ROIC) | -51.97% |
| Revenue Per Employee | 1.40M |
| Profits Per Employee | -4.85M |
| Employee Count | 168 |
| Asset Turnover | 0.18 |
| Inventory Turnover | 34.61 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +11.44% in the last 52 weeks. The beta is 1.44, so Hansa Biopharma AB's price volatility has been higher than the market average.
| Beta (5Y) | 1.44 |
| 52-Week Price Change | +11.44% |
| 50-Day Moving Average | 38.20 |
| 200-Day Moving Average | 38.71 |
| Relative Strength Index (RSI) | 35.36 |
| Average Volume (20 Days) | 167,588 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Hansa Biopharma AB had revenue of SEK 189.39 million and -654.78 million in losses. Loss per share was -11.09.
| Revenue | 189.39M |
| Gross Profit | 101.20M |
| Operating Income | -626.45M |
| Pretax Income | -654.36M |
| Net Income | -654.78M |
| EBITDA | -623.31M |
| EBIT | -626.45M |
| Loss Per Share | -11.09 |
Balance Sheet
The company has 553.54 million in cash and 959.19 million in debt, giving a net cash position of -405.64 million or -5.98 per share.
| Cash & Cash Equivalents | 553.54M |
| Total Debt | 959.19M |
| Net Cash | -405.64M |
| Net Cash Per Share | -5.98 |
| Equity (Book Value) | -319.96M |
| Book Value Per Share | -4.72 |
| Working Capital | 441.47M |
Cash Flow
In the last 12 months, operating cash flow was -700.03 million and capital expenditures 289,000, giving a free cash flow of -699.74 million.
| Operating Cash Flow | -700.03M |
| Capital Expenditures | 289,000 |
| Free Cash Flow | -699.74M |
| FCF Per Share | -10.32 |
Margins
| Gross Margin | 53.43% |
| Operating Margin | -330.77% |
| Pretax Margin | -345.51% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -369.47% |
Dividends & Yields
Hansa Biopharma AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -15.98% |
| Shareholder Yield | -15.98% |
| Earnings Yield | -36.24% |
| FCF Yield | -33.72% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |